Journal: Molecular Biology of the Cell
Article Title: Augmin shapes the anaphase spindle for efficient cytokinetic furrow ingression and abscission
doi: 10.1091/mbc.E15-02-0101
Figure Lengend Snippet: Defects in formation of the contractile ring in augmin-depleted cells. (A–D) Immunostaining for RhoA (A), myosin IIA heavy chain (B), and anillin (D) or staining of F-actin by rhodamine-phalloidin (C) in RNAi-treated cells. MTs were visualized by either immunostaining (B, D) or EGFP–α-tubulin (A, C). (E) Left, for quantification in F and G, the dividing cells were categorized based on the progression of furrow ingression, which was quantified using a furrowing index, defined as (1 – furrow width/cell length). See Materials and Methods for details. Middle and right, example of an ROI used for quantification in F (a line profile across the division plane, green) and G (a line profile along the cortex, magenta). The light blue box indicates the cytoplasmic region used for background subtraction. (F) Normalized intensity of RhoA, myosin IIA, F-actin, or anillin staining at the cleavage furrow during the progression of furrowing. Each data point corresponds to the average of two peak intensities of a line profile (E) from each single cell. Data points were binned at a 0.2 interval of the furrowing index, and the mean ± SE of the bins is shown as squares with a line. Data were normalized to the mean intensity of controls at the bin of the furrowing index 0.6–0.8. At least 24 cells (RhoA), ≥28 cells (myosin IIA), ≥32 cells (F-actin), or ≥24 cells (anillin) from at least two independent experiments per condition were analyzed. Depletion of Aug6 significantly decreased anillin accumulation at the cleavage furrow (* p < 0.05, ** p < 0.01, *** p < 0.001; t test). (G) Normalized intensities of RhoA, myosin IIA, F-actin, and anillin along the cell cortex. Data from the cells with a furrowing index of 0.4–0.6 (corresponding to the furrowing phase). Two line profiles were derived from both sides of each single cell. Mean ± SE of ≥8 cells (RhoA), ≥6 cells (myosin IIA), ≥13 cells (F-actin), or ≥9 cells (anillin) from at least two independent experiments per condition. Scale bars, 5 μm.
Article Snippet: Rat monoclonal anti–α-tubulin antibody (YOL1/34; AbD Serotec, Raleigh, NC), mouse monoclonal anti-aurora B antibody (611082; BD Biosciences, Franklin Lakes, NJ), rabbit monoclonal anti-PRC1 antibody (ab51248; Abcam, Cambridge, United Kingdom), goat polyclonal anti-PRC1 antibodies (sc-9342; Santa Cruz Biotechnology, Dallas, TX), mouse monoclonal anti-NEDD1 antibody (H00121441-M05; Abnova, Taipei, Taiwan), goat polyclonal anti-anillin antibodies (sc-54859; Santa Cruz Biotechnology), rabbit polyclonal anti-ECT2 antibody (sc-1005; Santa Cruz Biotechnology), goat polyclonal anti–citron kinase (sc-1848; Santa Cruz Biotechnology), mouse monoclonal anti-RhoA antibody (sc-418; Santa Cruz Biotechnology), and rat monoclonal anti-GFP (GF090R; Nacalai Tesque, Kyoto, Japan) were purchased from suppliers as indicated.
Techniques: Immunostaining, Staining, Derivative Assay